
IDEXX Laboratories (IDXX) Stock Forecast & Price Target
IDEXX Laboratories (IDXX) Analyst Ratings
Bulls say
IDEXX Laboratories maintains a strong customer retention rate of approximately 97%, which enhances the predictability of its revenue and earnings streams. The company has also demonstrated robust organic consumables recurring revenue growth, achieving a compound annual growth rate (CAGR) of approximately 16% from 2016 to 2022. With expectations of expanding clinical visits and compelling growth benefits tied to its complete suite of offerings, IDEXX is well-positioned to capitalize on a potential recovery in pet patient visits and overall market growth.
Bears say
IDEXX Laboratories has experienced a consistent decline in clinical vet visits, with a reported decrease of -1.7% year-over-year in Q4'25, reflecting a worsening trend since Q2'25's decline of -2.2%. This ongoing reduction in vet visits is anticipated to adversely impact the adoption rate of IDEXX's diagnostic products, creating potential headwinds for growth in a market increasingly sensitive to economic conditions, particularly among lower-income pet owners. Additionally, the broader economic challenges could lead to cash flow issues for both customers and suppliers, further diminishing demand for IDEXX's offerings and increasing the risk of revenue slowdown.
This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.
IDEXX Laboratories (IDXX) Analyst Forecast & Price Prediction
Start investing in IDEXX Laboratories (IDXX)
Order type
Buy in
Order amount
Est. shares
0 shares